Adefovir as a Novel Drug for the Treatment of Chronic Hepatitis B in Patients with End-Stage Renal Disease and Kidney Recipients

Abstract

Administration of adefovir dipivoxil (ADV) has been shown to provide an increased rate of hepatitis Be (HBe) seroconversion. It is also effective in the treatment of HIV. Because of its significant nephrotoxicity after 24 weeks of the treatment, this drug is no longer used for management of HIV. However, hepatitis B virus is inhibited with lower doses of ADV. The drug can even be used safely in those with renal impairment. This review provides new aspects of treatment of hepatitis B using ADV, especially in patients with renal dysfunction as well as renal transplant recipients. We showed that ADV can be used as a safe drug in renal transplant recipients.